The Elite Test Bank: 2026 Family
Nurse Practitioner (FNP) Cardiology
and OB/GYN Certification Report
PART I: THE PRIMER
Mastering the 2026 cardiovascular and obstetric guidelines separates competent practitioners
from elite diagnosticians, yielding high-level professional success through the prevention of
catastrophic morbidity. This test bank forges that mastery, transforming academic memorization
into rapid, high-stakes clinical intuition necessary for advanced practice.
● Hypertension (HTN) Target: Universal target is <130/80 mmHg; pharmacotherapy
initiates when PREVENT 10-year risk is \ge7.5%.
● Pregnancy HTN: The CHAP protocol mandates treating chronic hypertension in
pregnancy to <140/90 mmHg.
● Heart Failure (HFpEF): SGLT2 inhibitors and GLP-1 receptor agonists are foundational
for modifying morbidity and adiposity.
● Cervical Cancer Screening: High-risk HPV (hrHPV) self-collection is the preferred
modality for average-risk individuals aged 30-65.
● STI Management: Bicillin L-A is strictly reserved for pregnant patients; non-pregnant
primary syphilis requires Doxycycline 100mg BID.
PART II: THE ELITE TEST BANK
Questions 1–15: Foundational Syntax & Application
Q1: Under the 2025/2026 ACC/AHA hypertension guidelines, which of the following
variables is explicitly excluded from the PREVENT risk calculator due to its classification
as a social rather than a biological construct? A) Social Deprivation Index (SDI) B)
Hemoglobin A1c (HbA1c) C) Patient Race D) Urine albumin-creatinine ratio (UACR)
● The Answer: C (Patient Race).
● Distractor Analysis: Options A, B, and D represent newly incorporated or optional
variables within the PREVENT calculator designed to refine risk assessment. The SDI
explicitly accounts for structural determinants of health, while UACR and HbA1c integrate
renal and metabolic parameters.
● The Mentor's Analysis: The transition from the legacy Pooled Cohort Equations (PCE)
to the PREVENT calculator represents a paradigm shift in cardiovascular risk
assessment. Race was eliminated to remove inherent algorithmic biases and
acknowledge race as a social construct. The elite clinician utilizes the PREVENT tool to
estimate comprehensive 10-year and 30-year total cardiovascular disease risk,
encompassing heart failure alongside atherosclerotic events, which redefines
Cardiovascular-Kidney-Metabolic (CKM) health.
,Q2: Based on the CHAP trial and the 2026 ACOG guidelines, what is the hard-deck blood
pressure threshold for initiating or titrating antihypertensive pharmacotherapy in
pregnant patients with mild chronic hypertension? A) \ge160/110 mmHg B) \ge150/100
mmHg C) \ge140/90 mmHg D) \ge130/80 mmHg
● The Answer: C (\ge140/90 mmHg).
● Distractor Analysis: Option A reflects obsolete, pre-2022 guidelines that withheld
treatment until severe-range hypertension occurred to theoretically avoid fetal growth
restriction. Option D is the aggressive target for non-pregnant adults under AHA
guidelines but lacks validation for placental perfusion.
● The Mentor's Analysis: The CHAP trial fundamentally rewrote obstetric cardiology
protocols. Treating mild chronic hypertension to a target of <140/90 mmHg demonstrably
reduces the composite risk of severe preeclampsia, placental abruption, and medically
indicated preterm birth without increasing the incidence of small-for-gestational-age
neonates. First-line agents remain labetalol or nifedipine.
Q3: The 2026 Health Resources and Services Administration (HRSA) and American
Cancer Society (ACS) guidelines establish which primary screening modality as the
preferred option for average-risk females aged 30 to 65? A) Annual clinician-collected
cervical cytology (Pap test) B) Triennial clinician-collected cotesting C) Primary hrHPV testing
via patient self-collection D) Transvaginal ultrasound with CA-125
● The Answer: C (Primary hrHPV testing via patient self-collection).
● Distractor Analysis: Option A relies on outdated frequency intervals and less sensitive
cytology. Option B remains an acceptable alternative but is no longer the vanguard
preference. Option D is an unvalidated, irrelevant metric for cervical cancer screening.
● The Mentor's Analysis: By 2026, self-collected vaginal specimens for hrHPV testing
represent the primary mechanism for expanding screening access and equity. If the
self-collected hrHPV test yields a negative result, the subsequent screening interval is
established at three years. This methodology reduces clinical bottlenecks and patient
anxiety while maintaining unparalleled sensitivity for precancerous lesions.
Q4: A 28-year-old men who have sex with men (MSM) patient requests post-exposure
prophylaxis for bacterial STIs. According to CDC guidelines, what is the exact dosing
parameter for Doxy-PEP? A) 100 mg of doxycycline taken daily as PrEP B) 200 mg of
doxycycline taken within 72 hours of sexual exposure, not to exceed 200 mg per 24 hours C)
500 mg of ceftriaxone IM within 24 hours of exposure D) 100 mg of doxycycline taken within 12
hours of exposure
● The Answer: B (200 mg of doxycycline taken within 72 hours of sexual exposure, not to
exceed 200 mg per 24 hours).
● Distractor Analysis: Option A fatally confuses post-exposure prophylaxis with daily
pre-exposure prophylaxis. Option C is the definitive treatment for established
uncomplicated gonorrhea. Option D dictates an incorrect dose and an overly restrictive
time window.
● The Mentor's Analysis: Doxy-PEP serves as a targeted intervention specifically for MSM
and transgender women harboring a history of bacterial STIs. The 200 mg dose must be
ingested within the 72-hour window post-exposure. The clinician is required to ensure the
patient comprehends the 24-hour maximum threshold to prevent systemic toxicity, while
simultaneously advising administration with copious water to avert esophageal irritation.
Q5: Following the FDA boxed warning update for the menopausal neurokinin 3 (NK3)
receptor antagonist Veozah (fezolinetant), what mandatory laboratory monitoring
protocol must be instituted? A) Annual lipid panels and coagulation studies B) Monthly liver
, blood testing for the first two months, then at months 3, 6, and 9 C) Weekly complete blood
counts (CBC) for the first month D) Baseline renal function tests with no further monitoring
required
● The Answer: B (Monthly liver blood testing for the first two months, then at months 3, 6,
and 9).
● Distractor Analysis: Options A and C surveil the wrong physiological systems. Option D
constitutes clinical negligence by ignoring the explicit FDA boxed warning regarding
unpredictable hepatic toxicity.
● The Mentor's Analysis: Fezolinetant stands as a breakthrough non-hormonal therapy for
vasomotor symptoms (VMS). However, rare but severe drug-induced liver injury
necessitates a rigid surveillance apparatus. The elite practitioner recognizes that
prescribing this medication is contingent upon systemic safety protocols; any clinically
significant elevation in liver function tests dictates immediate, permanent cessation of the
pharmaceutical agent.
Q6: Due to the ongoing 2025/2026 supply chain shortage of Bicillin L-A (Penicillin G
benzathine), the CDC mandates prioritizing this medication exclusively for which clinical
demographic? A) Immunocompromised patients exhibiting neurosyphilis B) Non-pregnant
adults diagnosed with latent syphilis C) Pregnant patients infected with or exposed to syphilis D)
Pediatric patients presenting with atypical pneumonia
● The Answer: C (Pregnant patients infected with or exposed to syphilis).
● Distractor Analysis: Option A necessitates IV aqueous crystalline penicillin G, not
benzathine preparations. Options B and D represent inappropriate squandering of a
scarce resource; non-pregnant adults must be diverted to doxycycline regimens.
● The Mentor's Analysis: Congenital syphilis represents a devastating, entirely
preventable outcome. Penicillin G benzathine serves as the singular validated,
recommended therapy for pregnant patients capable of successfully crossing the
placental barrier to treat the fetus. When international supply chains fracture, ethical
resource allocation must rigidly shield the most vulnerable phenotypes, overriding
standard protocols for non-pregnant cohorts.
Q7: The 2026 ACC/AHA guidelines emphasize the Cardiovascular-Kidney-Metabolic
(CKM) syndrome. Stage 2 CKM syndrome is specifically defined by the presence of which
physiological factors? A) Excess or dysfunctional adiposity devoid of other risk factors B)
Subclinical cardiovascular disease (e.g., elevated coronary artery calcium) C) Clinical heart
failure with preserved ejection fraction D) Established metabolic risk factors (e.g., Type 2
diabetes, high triglycerides, or CKD)
● The Answer: D (Established metabolic risk factors (e.g., Type 2 diabetes, high
triglycerides, or CKD)).
● Distractor Analysis: Option A precisely describes Stage 1. Option B describes the
progression into Stage 3. Option C defines end-stage, or Stage 4, disease.
● The Mentor's Analysis: CKM syndrome acknowledges the inseparable
pathophysiological triad of the heart, kidneys, and systemic metabolism. Stage 2 identifies
the critical clinical inflection point where metabolic disease or chronic kidney disease has
manifested, yet gross structural cardiovascular disease remains absent. This specific
stage mandates aggressive pharmacological intervention to halt the trajectory toward
irreversible subclinical disease.
CKM Syndrome Staging Clinical Definition
Stage 0 Zero CKM risk factors present.
Nurse Practitioner (FNP) Cardiology
and OB/GYN Certification Report
PART I: THE PRIMER
Mastering the 2026 cardiovascular and obstetric guidelines separates competent practitioners
from elite diagnosticians, yielding high-level professional success through the prevention of
catastrophic morbidity. This test bank forges that mastery, transforming academic memorization
into rapid, high-stakes clinical intuition necessary for advanced practice.
● Hypertension (HTN) Target: Universal target is <130/80 mmHg; pharmacotherapy
initiates when PREVENT 10-year risk is \ge7.5%.
● Pregnancy HTN: The CHAP protocol mandates treating chronic hypertension in
pregnancy to <140/90 mmHg.
● Heart Failure (HFpEF): SGLT2 inhibitors and GLP-1 receptor agonists are foundational
for modifying morbidity and adiposity.
● Cervical Cancer Screening: High-risk HPV (hrHPV) self-collection is the preferred
modality for average-risk individuals aged 30-65.
● STI Management: Bicillin L-A is strictly reserved for pregnant patients; non-pregnant
primary syphilis requires Doxycycline 100mg BID.
PART II: THE ELITE TEST BANK
Questions 1–15: Foundational Syntax & Application
Q1: Under the 2025/2026 ACC/AHA hypertension guidelines, which of the following
variables is explicitly excluded from the PREVENT risk calculator due to its classification
as a social rather than a biological construct? A) Social Deprivation Index (SDI) B)
Hemoglobin A1c (HbA1c) C) Patient Race D) Urine albumin-creatinine ratio (UACR)
● The Answer: C (Patient Race).
● Distractor Analysis: Options A, B, and D represent newly incorporated or optional
variables within the PREVENT calculator designed to refine risk assessment. The SDI
explicitly accounts for structural determinants of health, while UACR and HbA1c integrate
renal and metabolic parameters.
● The Mentor's Analysis: The transition from the legacy Pooled Cohort Equations (PCE)
to the PREVENT calculator represents a paradigm shift in cardiovascular risk
assessment. Race was eliminated to remove inherent algorithmic biases and
acknowledge race as a social construct. The elite clinician utilizes the PREVENT tool to
estimate comprehensive 10-year and 30-year total cardiovascular disease risk,
encompassing heart failure alongside atherosclerotic events, which redefines
Cardiovascular-Kidney-Metabolic (CKM) health.
,Q2: Based on the CHAP trial and the 2026 ACOG guidelines, what is the hard-deck blood
pressure threshold for initiating or titrating antihypertensive pharmacotherapy in
pregnant patients with mild chronic hypertension? A) \ge160/110 mmHg B) \ge150/100
mmHg C) \ge140/90 mmHg D) \ge130/80 mmHg
● The Answer: C (\ge140/90 mmHg).
● Distractor Analysis: Option A reflects obsolete, pre-2022 guidelines that withheld
treatment until severe-range hypertension occurred to theoretically avoid fetal growth
restriction. Option D is the aggressive target for non-pregnant adults under AHA
guidelines but lacks validation for placental perfusion.
● The Mentor's Analysis: The CHAP trial fundamentally rewrote obstetric cardiology
protocols. Treating mild chronic hypertension to a target of <140/90 mmHg demonstrably
reduces the composite risk of severe preeclampsia, placental abruption, and medically
indicated preterm birth without increasing the incidence of small-for-gestational-age
neonates. First-line agents remain labetalol or nifedipine.
Q3: The 2026 Health Resources and Services Administration (HRSA) and American
Cancer Society (ACS) guidelines establish which primary screening modality as the
preferred option for average-risk females aged 30 to 65? A) Annual clinician-collected
cervical cytology (Pap test) B) Triennial clinician-collected cotesting C) Primary hrHPV testing
via patient self-collection D) Transvaginal ultrasound with CA-125
● The Answer: C (Primary hrHPV testing via patient self-collection).
● Distractor Analysis: Option A relies on outdated frequency intervals and less sensitive
cytology. Option B remains an acceptable alternative but is no longer the vanguard
preference. Option D is an unvalidated, irrelevant metric for cervical cancer screening.
● The Mentor's Analysis: By 2026, self-collected vaginal specimens for hrHPV testing
represent the primary mechanism for expanding screening access and equity. If the
self-collected hrHPV test yields a negative result, the subsequent screening interval is
established at three years. This methodology reduces clinical bottlenecks and patient
anxiety while maintaining unparalleled sensitivity for precancerous lesions.
Q4: A 28-year-old men who have sex with men (MSM) patient requests post-exposure
prophylaxis for bacterial STIs. According to CDC guidelines, what is the exact dosing
parameter for Doxy-PEP? A) 100 mg of doxycycline taken daily as PrEP B) 200 mg of
doxycycline taken within 72 hours of sexual exposure, not to exceed 200 mg per 24 hours C)
500 mg of ceftriaxone IM within 24 hours of exposure D) 100 mg of doxycycline taken within 12
hours of exposure
● The Answer: B (200 mg of doxycycline taken within 72 hours of sexual exposure, not to
exceed 200 mg per 24 hours).
● Distractor Analysis: Option A fatally confuses post-exposure prophylaxis with daily
pre-exposure prophylaxis. Option C is the definitive treatment for established
uncomplicated gonorrhea. Option D dictates an incorrect dose and an overly restrictive
time window.
● The Mentor's Analysis: Doxy-PEP serves as a targeted intervention specifically for MSM
and transgender women harboring a history of bacterial STIs. The 200 mg dose must be
ingested within the 72-hour window post-exposure. The clinician is required to ensure the
patient comprehends the 24-hour maximum threshold to prevent systemic toxicity, while
simultaneously advising administration with copious water to avert esophageal irritation.
Q5: Following the FDA boxed warning update for the menopausal neurokinin 3 (NK3)
receptor antagonist Veozah (fezolinetant), what mandatory laboratory monitoring
protocol must be instituted? A) Annual lipid panels and coagulation studies B) Monthly liver
, blood testing for the first two months, then at months 3, 6, and 9 C) Weekly complete blood
counts (CBC) for the first month D) Baseline renal function tests with no further monitoring
required
● The Answer: B (Monthly liver blood testing for the first two months, then at months 3, 6,
and 9).
● Distractor Analysis: Options A and C surveil the wrong physiological systems. Option D
constitutes clinical negligence by ignoring the explicit FDA boxed warning regarding
unpredictable hepatic toxicity.
● The Mentor's Analysis: Fezolinetant stands as a breakthrough non-hormonal therapy for
vasomotor symptoms (VMS). However, rare but severe drug-induced liver injury
necessitates a rigid surveillance apparatus. The elite practitioner recognizes that
prescribing this medication is contingent upon systemic safety protocols; any clinically
significant elevation in liver function tests dictates immediate, permanent cessation of the
pharmaceutical agent.
Q6: Due to the ongoing 2025/2026 supply chain shortage of Bicillin L-A (Penicillin G
benzathine), the CDC mandates prioritizing this medication exclusively for which clinical
demographic? A) Immunocompromised patients exhibiting neurosyphilis B) Non-pregnant
adults diagnosed with latent syphilis C) Pregnant patients infected with or exposed to syphilis D)
Pediatric patients presenting with atypical pneumonia
● The Answer: C (Pregnant patients infected with or exposed to syphilis).
● Distractor Analysis: Option A necessitates IV aqueous crystalline penicillin G, not
benzathine preparations. Options B and D represent inappropriate squandering of a
scarce resource; non-pregnant adults must be diverted to doxycycline regimens.
● The Mentor's Analysis: Congenital syphilis represents a devastating, entirely
preventable outcome. Penicillin G benzathine serves as the singular validated,
recommended therapy for pregnant patients capable of successfully crossing the
placental barrier to treat the fetus. When international supply chains fracture, ethical
resource allocation must rigidly shield the most vulnerable phenotypes, overriding
standard protocols for non-pregnant cohorts.
Q7: The 2026 ACC/AHA guidelines emphasize the Cardiovascular-Kidney-Metabolic
(CKM) syndrome. Stage 2 CKM syndrome is specifically defined by the presence of which
physiological factors? A) Excess or dysfunctional adiposity devoid of other risk factors B)
Subclinical cardiovascular disease (e.g., elevated coronary artery calcium) C) Clinical heart
failure with preserved ejection fraction D) Established metabolic risk factors (e.g., Type 2
diabetes, high triglycerides, or CKD)
● The Answer: D (Established metabolic risk factors (e.g., Type 2 diabetes, high
triglycerides, or CKD)).
● Distractor Analysis: Option A precisely describes Stage 1. Option B describes the
progression into Stage 3. Option C defines end-stage, or Stage 4, disease.
● The Mentor's Analysis: CKM syndrome acknowledges the inseparable
pathophysiological triad of the heart, kidneys, and systemic metabolism. Stage 2 identifies
the critical clinical inflection point where metabolic disease or chronic kidney disease has
manifested, yet gross structural cardiovascular disease remains absent. This specific
stage mandates aggressive pharmacological intervention to halt the trajectory toward
irreversible subclinical disease.
CKM Syndrome Staging Clinical Definition
Stage 0 Zero CKM risk factors present.
